(HealthDay)—An experimental therapy for hepatitis C—a "silent killer" linked to liver cancer and cirrhosis—has shown promise in tamping down virus levels in early trials.
5 / 5 (3) |
1
|
(HealthDay)—In patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC), low HCV viral load predicts better long-term surgical outcomes, regardless of the serologic eradication of HCV, ...
not rated yet |
0
The drug telaprevir (trade name: Incivo) has been available for treatment of chronic hepatitis C infection of genotype 1 since autumn 2011. In an early benefit assessment pursuant to the "Act on the Reform of the Market for ...
not rated yet |
0
New data from a number of clinical trials presented for the first time at the International Liver Congress 2012 provides hope for previously difficult to treat hepatitis C (HCV) patient populations.
not rated yet |
0
A new combination of investigational drugs successfully suppressed hepatitis C genotype 1 infection in a high percent of patients who had not responded to previous treatment in a study led by a University of Michigan hepatologist.
not rated yet |
0
|
A human monoclonal antibody developed by MassBiologics of the University of Massachusetts Medical School (UMMS) given to patients with chronic hepatitis C virus (HCV) infection undergoing liver transplantation significantly ...
not rated yet |
0
